Matrix metalloproteinases in T cell mediated pulmonary diseases

Heather Lynette Benson, David Stephen Wilkes

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Lung transplantation is the only conclusive treatment for many patients suffering from end-stage pulmonary disease. Unfortunately, the leading cause of death in lung transplant recipients is the development of chronic rejection known as obliterative bronchiolitis, characterized by extensive remodeling. Matrix metalloproteinases (MMPs) are endopeptidases known for their role in matrix remodeling and their involvement in many biological processes including end-stage pulmonary disease and transplant rejection. Our understanding of MMPs involvement in pulmonary immunity is rapidly expanding. As a result there has been some focus on MMPs role in T cell-associated pulmonary diseases, such as pulmonary fibrosis, emphysema, asthma and bronchiolitis obliterans syndrome. However, not much is known about the role of MMPs in regulating immune cell function. It is now commonly known that MMP inhibition via, broad spectrum or specific synthetic or naturally occurring inhibitors (TIMPs) can down regulated many pulmonary disease states. In this review, we explore the idea that T cell targeted MMP inhibition may provide a novel approach of immune regulation in the treatment of T cell-mediated diseases.

Original languageEnglish (US)
Pages (from-to)2162-2169
Number of pages8
JournalFrontiers in Bioscience - Elite
Volume4 E
Issue number6
StatePublished - Jan 1 2012

    Fingerprint

Keywords

  • Lung transplantation
  • Matrix metalloproteinases
  • MMP
  • Review
  • T cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this